User login
Key clinical point: An induction treatment of 200 mg abrocitinib followed by dose reduction (100 mg) or continuous dosing (200 mg) is efficacious and safe in adults and adolescents with moderate-to-severe atopic dermatitis (AD).
Major finding: In the 200 mg abrocitinib, 100 mg abrocitinib, and placebo arms, similar proportions of adolescents and adults experienced disease flare (14.9% and 16.9%, 42.9% and 38.9%, and 75.5% and 78.0%, respectively) and the Eczema Area and Severity Index response was recaptured by 28.6%, 25.0%, and 52.9% of adolescents and 34.3%, 33.7%, and 58.0% of adults, respectively. The safety profile was consistent in adolescents and adults.
Study details: This post hoc analysis of the JADE REGIMEN study included 246 adolescents (12-17 years) and 987 adults with moderate-to-severe AD who received 200 mg abrocitinib induction treatment; responders were randomly assigned to receive 40-week abrocitinib (200/100 mg) or placebo maintenance treatment and rescue treatment (if disease flared).
Disclosures: Pfizer Inc funded the study. Some authors reported various ties, including employment and stock ownership, with Pfizer or others.
Source: Flohr C et al. Efficacy and safety of abrocitinib monotherapy in adolescents and adults: A post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial. J Dermatolog Treat. 2023;1-13 (Apr 10). Doi: 10.1080/09546634.2023.2200866
Key clinical point: An induction treatment of 200 mg abrocitinib followed by dose reduction (100 mg) or continuous dosing (200 mg) is efficacious and safe in adults and adolescents with moderate-to-severe atopic dermatitis (AD).
Major finding: In the 200 mg abrocitinib, 100 mg abrocitinib, and placebo arms, similar proportions of adolescents and adults experienced disease flare (14.9% and 16.9%, 42.9% and 38.9%, and 75.5% and 78.0%, respectively) and the Eczema Area and Severity Index response was recaptured by 28.6%, 25.0%, and 52.9% of adolescents and 34.3%, 33.7%, and 58.0% of adults, respectively. The safety profile was consistent in adolescents and adults.
Study details: This post hoc analysis of the JADE REGIMEN study included 246 adolescents (12-17 years) and 987 adults with moderate-to-severe AD who received 200 mg abrocitinib induction treatment; responders were randomly assigned to receive 40-week abrocitinib (200/100 mg) or placebo maintenance treatment and rescue treatment (if disease flared).
Disclosures: Pfizer Inc funded the study. Some authors reported various ties, including employment and stock ownership, with Pfizer or others.
Source: Flohr C et al. Efficacy and safety of abrocitinib monotherapy in adolescents and adults: A post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial. J Dermatolog Treat. 2023;1-13 (Apr 10). Doi: 10.1080/09546634.2023.2200866
Key clinical point: An induction treatment of 200 mg abrocitinib followed by dose reduction (100 mg) or continuous dosing (200 mg) is efficacious and safe in adults and adolescents with moderate-to-severe atopic dermatitis (AD).
Major finding: In the 200 mg abrocitinib, 100 mg abrocitinib, and placebo arms, similar proportions of adolescents and adults experienced disease flare (14.9% and 16.9%, 42.9% and 38.9%, and 75.5% and 78.0%, respectively) and the Eczema Area and Severity Index response was recaptured by 28.6%, 25.0%, and 52.9% of adolescents and 34.3%, 33.7%, and 58.0% of adults, respectively. The safety profile was consistent in adolescents and adults.
Study details: This post hoc analysis of the JADE REGIMEN study included 246 adolescents (12-17 years) and 987 adults with moderate-to-severe AD who received 200 mg abrocitinib induction treatment; responders were randomly assigned to receive 40-week abrocitinib (200/100 mg) or placebo maintenance treatment and rescue treatment (if disease flared).
Disclosures: Pfizer Inc funded the study. Some authors reported various ties, including employment and stock ownership, with Pfizer or others.
Source: Flohr C et al. Efficacy and safety of abrocitinib monotherapy in adolescents and adults: A post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial. J Dermatolog Treat. 2023;1-13 (Apr 10). Doi: 10.1080/09546634.2023.2200866